Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft safety review: the rodent thyroid C-cell signal and its… — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-019/3
Series
Public comment period
Version
1.0
Published
13 Jun 2025
Last reviewed
13 Jun 2025
Next review
13 Jun 2026
Identifier
10.71829/cei.cp.19
Certainty
Not rated
Cycle
2025 Q2
Window
20 Apr 2025 – 20 May 2025
Status
Closed
Submissions
16

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-THYROID-C-CE/006Dr Frideswide Grünbaum-SowandeRisk-of-bias judgements are reported as an overall rating without the domainsAccepted
DRAFT-THYROID-C-CE/005Dr Delphine RavensworthReferences should carry a persistent identifier for every cited sourceAccepted in part
DRAFT-THYROID-C-CE/010Dr Quentin ZimmerthalA surrogate outcome is used as the anchor without validation evidenceAccepted in part
DRAFT-THYROID-C-CE/011Dr Emiliana OllerenshawPoint estimates are given without an intervalAccepted in part
DRAFT-THYROID-C-CE/003Dr Abimbola Sotomayor-EkwuemeAn indirect comparison is presented without an assessment of transitivityAccepted
DRAFT-THYROID-C-CE/016Dr Lorcan Whitmarsh-ObiThe search strategy as published cannot be re-runAccepted
DRAFT-THYROID-C-CE/009Brigitta Grünbaum-SowandeAnalytical surveys are treated as evidence about suppliers when they establish only what was in a sampleAccepted
DRAFT-THYROID-C-CE/004Dr Ulysses Bellingham-Ojo industryA sponsor trial meeting the eligibility criteria was excludedAccepted in part
DRAFT-THYROID-C-CE/001Dr Wojciech Kaltenbach-MensahResults at materially different follow-up durations are pooledAccepted
DRAFT-THYROID-C-CE/013Dr Séverine Oduya-KaltenbrunnerA funnel plot is presented for a set too small to interpret itAccepted
DRAFT-THYROID-C-CE/002Dr Wolfram TollemacheTwo included studies do not meet the registered eligibility criteriaAccepted in part
DRAFT-THYROID-C-CE/015Dr Kolawole Isaksen-BalogunEfficacy outcomes are rated for certainty and harms are notAccepted
DRAFT-THYROID-C-CE/012Dr Quentin EnthovenThe document is unreadable without specialist trainingAccepted in part
DRAFT-THYROID-C-CE/008Dr Jerome LavrentievStatistical heterogeneity is treated as though it measured clinical heterogeneityAccepted in part
DRAFT-THYROID-C-CE/014Dr Liesbeth AchterbergRegistered trials that never reported are not counted anywhere in the reviewAccepted
DRAFT-THYROID-C-CE/007Professor Chukwuemeka Rasmussen-AdeyemiThe same concept is given three different names in one documentAccepted
16 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted9The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part7Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment0The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted0The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. Risk-of-bias judgements are reported as an overall rating without the domains — arising from DRAFT-THYROID-C-CE/006. Risk of bias is now reported at domain level for every included study, with the text on which each judgement was based quoted and referenced, and the overall judgement derived from the domains rather than asserted alongside them.
  2. References should carry a persistent identifier for every cited source — arising from DRAFT-THYROID-C-CE/005. Every reference without a persistent identifier now carries an explicit statement that the identifier is not held by the Institute, so that its absence is a recorded fact rather than an apparent oversight.
  3. A surrogate outcome is used as the anchor without validation evidence — arising from DRAFT-THYROID-C-CE/010. Where the anchor is a surrogate, the synthesis now states the evidence for the surrogate relationship, rates it separately, and downgrades the anchor rating for indirectness accordingly rather than carrying the surrogate as though it were the outcome of…
  4. Point estimates are given without an interval — arising from DRAFT-THYROID-C-CE/011. Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.
  5. An indirect comparison is presented without an assessment of transitivity — arising from DRAFT-THYROID-C-CE/003. Transitivity is now assessed against a stated list of effect modifiers and reported before any indirect estimate, and where the assessment fails the contrast is reported as unestimable with the reason rather than estimated with a caveat.
  6. The search strategy as published cannot be re-run — arising from DRAFT-THYROID-C-CE/016. The full line-by-line strategy for each database is now published with the interface, the run date and the yield at each line, and the total retrieved is reconciled against the screening flow.
  7. Analytical surveys are treated as evidence about suppliers when they establish only what was in a… — arising from DRAFT-THYROID-C-CE/009. Provenance is now assessed for every included survey and reported as a study characteristic, surveys without establishable provenance are reported separately rather than pooled with those that have it, and no supplier-level inference is drawn from a…
  8. A sponsor trial meeting the eligibility criteria was excluded — arising from DRAFT-THYROID-C-CE/004. The trial is added to the included set, the estimate and the certainty rating have been recomputed, and the screening record now states why the trial was missed, which was a database indexing gap rather than a screening judgement. The submission is identified…
  9. Results at materially different follow-up durations are pooled — arising from DRAFT-THYROID-C-CE/001. Estimates are now reported by duration band, with the number of contributing trials and participants in each band stated, and no estimate is pooled across bands.
  10. A funnel plot is presented for a set too small to interpret it — arising from DRAFT-THYROID-C-CE/013. The funnel plot is removed for every outcome contributed by fewer than ten studies, and replaced by a statement that small-study effects could not be assessed at that number, together with the count of registered trials identified without posted results.
  11. Two included studies do not meet the registered eligibility criteria — arising from DRAFT-THYROID-C-CE/002. One study has been removed from the included set and the estimate recomputed, the exclusion reason for the third study has been corrected in the excluded-studies table, and the screening decisions are now recorded against the protocol version in force at the…
  12. Efficacy outcomes are rated for certainty and harms are not — arising from DRAFT-THYROID-C-CE/015. Every reported harm now carries a certainty rating on the same scale as the efficacy outcomes, with the downgrade reasons stated, and discontinuation for adverse events appears in the summary of findings rather than in an annex.
  13. The document is unreadable without specialist training — arising from DRAFT-THYROID-C-CE/012. Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.
  14. Statistical heterogeneity is treated as though it measured clinical heterogeneity — arising from DRAFT-THYROID-C-CE/008. The decision to pool is now justified in prose against the population, intervention, comparator and outcome before any statistic is presented, and the heterogeneity statistic is reported with its confidence interval and a note of the number of contributing…
  15. Registered trials that never reported are not counted anywhere in the review — arising from DRAFT-THYROID-C-CE/014. Registered trials without posted results are now identified, counted and reported as a distinct category in the screening flow, with the proportion of registered participants they represent stated in the limitations.
  16. The same concept is given three different names in one document — arising from DRAFT-THYROID-C-CE/007. A single term is now used throughout for each defined concept, and the glossary entry is linked at first use within each section rather than once per document.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.